Jacobs Levy Equity Management’s Charles River Laboratories CRL Stock Holding History

Jacobs Levy Equity Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-12,776	Closed	-$1.81M	–	930
2019 Q2	$1.81M	Sell	12,776 -100	-0.8%	-$13.6K	0.03%	542
2019 Q1	$1.87M	Sell	12,876 -49,766	-79%	-$6.54M	0.03%	519
2018 Q4	$7.09M	Sell	62,642 -110	-0.2%	-$13.8K	0.12%	186
2018 Q3	$8.44M	Buy	62,752 +41,922	+201%	+$5.17M	0.12%	202
2018 Q2	$2.34M	Buy	20,830 +16,930	+434%	+$1.83M	0.04%	474
2018 Q1	$416K	Buy	+3,900	New	+$420K	0.01%	807
2017 Q2	–	Sell	-8,610	Closed	-$774K	–	945
2017 Q1	$774K	Sell	8,610 -33,660	-80%	-$2.86M	0.02%	597
2016 Q4	$3.22M	Buy	42,270 +90	+0.2%	+$6.83K	0.06%	324
2016 Q3	$3.52M	Sell	42,180 -45,830	-52%	-$3.84M	0.06%	321
2016 Q2	$7.26M	Sell	88,010 -32,470	-27%	-$2.67M	0.15%	191
2016 Q1	$9.15M	Sell	120,480 -19,830	-14%	-$1.47M	0.19%	155
2015 Q4	$11.3M	Sell	140,310 -15,400	-10%	-$1.11M	0.22%	137
2015 Q3	$9.89M	Buy	155,710 +44,060	+39%	+$3.16M	0.2%	147
2015 Q2	$7.85M	Buy	111,650 +43,110	+63%	+$3.19M	0.15%	175
2015 Q1	$5.43M	Buy	+68,540	New	+$5.06M	0.09%	220
2014 Q4	–	Sell	-6,000	Closed	-$358K	–	837
2014 Q3	$358K	Sell	6,000 -11,820	-66%	-$676K	0.01%	644
2014 Q2	$954K	Sell	17,820 -9,650	-35%	-$530K	0.02%	521
2014 Q1	$1.66M	Buy	+27,470	New	+$1.6M	0.03%	432

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Jacobs Levy Equity Management's CRL Position: Q3 2019 in Review

Jacobs Levy Equity Management sold out of Charles River Laboratories (CRL) in Q3 2019, closing a stake of 12,776 shares — an estimated $1.81M sold.

Jacobs Levy Equity Management first reported a position in CRL in Q1 2014 and held it in 18 quarters. The position peaked at $11.3M in Q4 2015. 396 funds tracked by Wall St. Rank hold CRL as of Q3 2019.

Jacobs Levy Equity Management reported no remaining Charles River Laboratories position as of Q3 2019 after selling out during the quarter.
Jacobs Levy Equity Management sold 12,776 Charles River Laboratories shares in Q3 2019, an estimated $1.81M.
Jacobs Levy Equity Management first reported a position in Charles River Laboratories in Q1 2014 and held it in 18 quarters.
Jacobs Levy Equity Management's Charles River Laboratories position peaked at $11.3M in Q4 2015.
396 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2019.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2019, filed 14 Nov 2019.